The Effects of Ezetimibe/Simvastatin versus Simvastatin Monotherapy on Platelet and Inflammatory Biomarkers in Patients with Metabolic SyndromeMiller M.a · DiNicolantonio J.J.b · Can M.b · Grice R.a · Damoulakis A.a · Serebruany V.L.b
aDepartment of Medicine, University of Maryland School of Medicine, Baltimore, Md., and bHeartDrug™ Research Laboratories, Johns Hopkins University, Towson, Md., USA
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
In a randomized, double-blind, crossover study of 15 aspirin-naive patients (mean age 48.8 ± 10.2 years) with the metabolic syndrome, statin monotherapy (simvastatin 40 mg daily) was compared to combination therapy (simvastatin 40 mg and ezetimibe 10 mg daily) on biomarkers of inflammation and platelet activity. The addition of ezetimibe to simvastatin over a 4-week period was associated with reduced expression of CD141 (thrombomodulin; p = 0.02), platelet endothelial cell adhesion molecule (p < 0.0001) and CD51/61 (vitronectin receptor; p = 0.048) compared to statin monotherapy. Ezetimibe added to simvastatin improves several indices of platelet reactivity beyond statin monotherapy. However, the clinical relevance of these findings await results of the IMPROVE-IT trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).
© 2013 S. Karger AG, Basel
- Serebruany VL, Miller M, Pokov AN, Malinin AI, Lowry DR, Tanguay J-F, Hennekens CH: Statins inhibit platelet PAR-1 thrombin receptor in patients with metabolic syndrome: the PAR-1 Inhibition by Statins (PARIS) Study. Am J Cardiol 2006;79:1332-1336.
- Palomo I, Moore-Carrasco R, Alarcon M, Rojas A, Espana F, Andres V, Gonzalez-Navarro H: Pathophysiology of the proatherothrombotic state in the metabolic syndrome. Front Biosci 2010;2:194-208.
- Swislocki AL, Siegel D, Jialal I: Pharmacotherapy for the metabolic syndrome. Curr Vasc Pharmacol 2012;10:187-205.
- Joy TR, Hegele RA: Narrative review: statin-related myopathy. Ann Intern Med 2009;150:858-868.
- Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA 2001;285:2486-2497.
- Miller M, Beach V, Sorkin JD, Mangano C, Dobmeier C, Novacic D, Rhyne J, Vogel RA: Comparative effects of three popular diets on lipids, endothelial function, and C-reactive protein during weight maintenance. J Am Diet Assoc 2009;109:713-717.
- Undas A, Machnik A, Potaczek DP, Wypasek E, Zmudka K, Tracz W: Ezetimibe combined with simvastatin compared with simvastatin alone results in a greater suppression of oxidative stress and enhanced fibrinolysis in patients after acute coronary events. J Cardiovasc Pharmacol 2011;58:167-172.
- Krysiak R, Zmuda W, Okopien B: The effect of ezetimibe, administered alone or in combination with simvastatin, on lymphocyte cytokine release in patients with elevated cholesterol levels. J Intern Med 2012;271:32-42.
- Woodfin A, Voisin MB, Nourshargh S: PECAM-1: a multi-functional molecule in inflammation and vascular biology. Arterioscler Thromb Vasc Biol 2007;27:2514-2523.
Li YH, Shi GY, Wu HL: Thrombomodulin in the treatment of atherothrombotic diseases. Front Biosci (Schol Ed) 2009;1:33-38.
- Preissner KT, Reuning U: Vitronectin in vascular context: facets of a multitalented matricellular protein. Semin Thromb Hemost 2011;37:408-424.
- Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, Visseren FL, Sijbrands EJ, Trip MD, Stein EA, Gaudet D, Duivenvoorden R, Veltri EP, Marais AD, de Groot E, ENHANCE investigators: Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008;358:1431-1443.
- Taylor AJ, Villines TC, Stanek EJ, Devine PJ, Griffen L, Miller M, Weissman NJ, Turco M: Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009;361:2113-2122.
http://www.clinicaltrials.gov/ct2/results?term=improve+it (accessed November 21, 2012).
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.